SGP · SpyGlass Pharma, Inc. Common Stock

Summary

SpyGlass Pharma, Inc. filed an 8-K on March 9, 2026, announcing under Item 8.01 positive top-line 12-month clinical updates on its innovative Bimatopro via press release. The filing includes Exhibit 99.1, the press release dated March 9, 2026.

Key takeaways

• Press release issued on March 9, 2026
• Positive top-line 12-month clinical updates disclosed
• Product: innovative Bimatopro
• Item 8.01 - Other Events
• Exhibit 99.1: Press Release